Isentress Gets Unanimous Nod From Advisory Committee, But May Get Limited Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Discussion of the indication for Merck’s raltegravir centered on whether the HIV therapy should be approved only for the highly treatment-experienced population studied in clinical trials.